Summary
- bluebird had a rough 2020 but we are quickly approaching several key catalysts in 2021 that will transform the company's outlook and possibly inject some momentum into the share price.
- ZYNTEGLO has conditional approval in the EU for those with transfusion-dependent beta-thalassemia. The company is now taking aim at the pediatric and ?0/?0 genotype indications.
- I review some of the upcoming catalysts and discuss my plans for adding to my undersized BLUE position in the near term.
bluebird bio (BLUE) had miserable price action throughout 2020, whereas, the sector hit an all-time high with some of the top gene or cell therapy tickers trading up several hundred percent. Despite BLUE’s upside potential, the company could not generate enough enthusiasm to participate in the sector’s rally, and the stock has continued to hover near the 52-week low. Personally, I believe ZYNTEGLO’s commercial launch in the EU and upcoming catalysts make BLUE worthy of a speculative buy at these prices.
Image Source: BLUE
I will review some of the recent developments and point out a few important catalysts that could reignite some enthusiasm in the ticker. In addition, I will reveal my plans to add to and manage my BLUE position in the coming years.
